Literature DB >> 16707602

Clinical significance of TROP2 expression in colorectal cancer.

Takahiro Ohmachi1, Fumiaki Tanaka, Koshi Mimori, Hiroshi Inoue, Katsuhiko Yanaga, Masaki Mori.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: To identify cancer-related genes, the expression profiles of colorectal cancer cells and normal epithelial cells were examined and compared using laser microdissection and cDNA microarray analysis. From these combined techniques, several cancer-related genes, including TROP2, were identified. TROP2 is known as a calcium signal transducer and is highly expressed in several types of tumors. However, no studies have investigated the significance of TROP2 expression in colorectal cancer. Thus, the expression status of TROP2 was investigated in 74 colorectal cancer samples by quantitative real-time reverse transcription-PCR and immunohistochemical studies.
RESULTS: Laser microdissection and cDNA microarray analysis showed that there were 84 overexpressed genes in cancer cells. One of the highly overexpressed genes was TROP2. Quantitative real-time reverse transcription-PCR showed that TROP2 expression in cancer samples was significantly higher than in normal samples (P < 0.001). The samples were divided into high (n = 26) and low (n = 48) TROP2 expression groups. The cases with high TROP2 expression showed a higher frequency of liver metastasis (P = 0.005) and more cancer-related death (P = 0.046). Those cases also had an inclination of deeper depth of invasion (P = 0.064) and more lymph node metastasis (P = 0.125). Interestingly, the patients with high TROP2 expression tumors had poorer prognosis (P = 0.0036). Multivariate analysis showed that TROP2 expression status was an independent prognostic factor (relative risk, 2.38; 95% confidence interval, 1.29-4.74; P < 0.01).
CONCLUSION: TROP2 is one of the cancer-related genes that correlates with biological aggressiveness and poor prognosis of colorectal cancer. Thus, TROP2 is a possible candidate gene for diagnosis and molecular target therapy of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707602     DOI: 10.1158/1078-0432.CCR-05-1961

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  81 in total

1.  siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells.

Authors:  Xiao-Yan Gao; Ye-Han Zhu; Li-Xin Zhang; Hui-Yu Lu; Ai-Gui Jiang
Journal:  Exp Ther Med       Date:  2015-05-28       Impact factor: 2.447

2.  Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway.

Authors:  Xi Wang; Min Long; Ke Dong; Fang Lin; Yuanyuan Weng; Yongri Ouyang; Li Liu; Junxia Wei; Xi Chen; Ting He; Hui-Zhong Zhang
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

3.  Targeting pancreatic progenitor cells in human embryonic stem cell differentiation for the identification of novel cell surface markers.

Authors:  Bettina Fishman; Hanna Segev; Oded Kopper; Jonathan Nissenbaum; Margarita Schulman; Nissim Benvenisty; Joseph Itskovitz-Eldor; Danny Kitsberg
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma.

Authors:  Hiromi Kobayashi; Yuko Minami; Yoichi Anami; Yuzuru Kondou; Tatsuo Iijima; Junko Kano; Yukio Morishita; Koji Tsuta; Shinichiro Hayashi; Masayuki Noguchi
Journal:  Virchows Arch       Date:  2010-05-16       Impact factor: 4.064

5.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.

Authors:  Tanya Stoyanova; Andrew S Goldstein; Houjian Cai; Justin M Drake; Jiaoti Huang; Owen N Witte
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

6.  Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway.

Authors:  H Nakanishi; C Taccioli; J Palatini; C Fernandez-Cymering; R Cui; T Kim; S Volinia; C M Croce
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

7.  Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis.

Authors:  Marco Trerotola; Jing Li; Saverio Alberti; Lucia R Languino
Journal:  J Cell Physiol       Date:  2012-11       Impact factor: 6.384

8.  Trop2 gene: a novel target for cervical cancer treatment.

Authors:  Xiaoqi Liu; Siqi Li; Faping Yi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553

9.  Prognostic value of TROP2 in human nasopharyngeal carcinoma.

Authors:  Guo-Fang Guan; De-Jun Zhang; Lian-Ji Wen; Duo-Jiao Yu; Yan Zhao; Lin Zhu; Ying-Yuan Guo; Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors.

Authors:  Shailendra Kapoor
Journal:  Tumour Biol       Date:  2012-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.